Nuvalent Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Public

  • Employees
  • 142

Employees

  • Stock Symbol
  • NUVL

Stock Symbol

  • Share Price
  • $73.48
  • (As of Friday Closing)

Nuvalent General Information

Description

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Contact Information

Website
www.nuvalent.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • One Broadway 14th Floor
  • Cambridge, MA 02142
  • United States
+1 (508)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • One Broadway 14th Floor
  • Cambridge, MA 02142
  • United States
+1 (508)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Nuvalent Stock Performance

As of 25-Apr-2025, Nuvalent’s stock price is $73.48. Its current market cap is $5.26B with 71.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$73.48 $73.98 $55.53 - $113.51 $5.26B 71.6M 558K -$3.93

Nuvalent Financials Summary

As of 31-Dec-2024, Nuvalent has a trailing 12-month revenue of null.

In Thousands,
USD 		TTM 31-Dec-2024 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022
EV 4,393,685 4,393,685 4,195,691 1,440,763
Revenue 0 0 0 0
EBITDA (298,308) (298,308) (149,492) (86,108)
Net Income (260,756) (260,756) (126,219) (81,854)
Total Assets 1,141,752 1,141,752 732,384 482,459
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Nuvalent Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Nuvalent‘s full profile, request access.

Request a free trial

Nuvalent Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion
Price		 % Owned

This information is available in the PitchBook Platform. To explore Nuvalent‘s full profile, request access.

Request a free trial

Nuvalent Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients
Drug Discovery
Cambridge, MA
142 As of 2024

Hayward, CA
 

Boston, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nuvalent Competitors (3)

One of Nuvalent’s 3 competitors is Arcus Biosciences, a Formerly VC-backed company based in Hayward, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Arcus Biosciences Formerly VC-backed Hayward, CA
AVEO Oncology Formerly VC-backed Boston, MA
Allogene Therapeutics Formerly VC-backed South San Francisco, CA
You’re viewing 3 of 3 competitors. Get the full list »

Nuvalent Patents

  • 41

    Total Documents Applications and Grants

  • Total Patents Families

  • 12

    Granted

  • 29

    Pending

  • Expiring in next 12 mo

Nuvalent Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023364043-A1 Heteroaromatic macrocyclic ether chemotherapeutic agents Pending 19-Oct-2022
US-20230322797-A1 Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds Pending 07-Apr-2022
AU-2023249641-A1 Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds Pending 07-Apr-2022
AU-2023249645-A1 Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine Pending 07-Apr-2022
EP-4504736-A1 Solid forms, pharmaceutical compositions and preparation of heteroaromatic macrocyclic ether compounds Pending 07-Apr-2022 C07D491/22
To view Nuvalent’s complete patent history, request access »

Nuvalent Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nuvalent Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Nuvalent‘s full profile, request access.

Request a free trial

Nuvalent ESG

Risk Overview

Risk Rating

Updated November, 30, 2024

35.51 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,109

Rank

Percentile

Pharmaceuticals

Industry

of 861

Rank

Percentile

Biotechnology

Subindustry

of 371

Rank

Percentile

To view Nuvalent’s complete esg history, request access »

Nuvalent FAQs

  • When was Nuvalent founded?

    Nuvalent was founded in 2017.

  • Where is Nuvalent headquartered?

    Nuvalent is headquartered in Cambridge, MA.

  • What is the size of Nuvalent?

    Nuvalent has 142 total employees.

  • What industry is Nuvalent in?

    Nuvalent’s primary industry is Drug Discovery.

  • Is Nuvalent a private or public company?

    Nuvalent is a Public company.

  • What is Nuvalent’s stock symbol?

    The ticker symbol for Nuvalent is NUVL.

  • What is the current stock price of Nuvalent?

    As of 25-Apr-2025 the stock price of Nuvalent is $73.48.

  • What is the current market cap of Nuvalent?

    The current market capitalization of Nuvalent is $5.26B.

  • Who are Nuvalent’s competitors?

    Arcus Biosciences, AVEO Oncology, and Allogene Therapeutics are competitors of Nuvalent.

  • What is Nuvalent’s annual earnings per share (EPS)?

    Nuvalent’s EPS for 12 months was -$3.93.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »